Compare Amgen, Inc. (AMGN) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs DuPont de Nemours Inc — how do they compare? Amgen, Inc. trades at $413.65 (market cap $224.14B), while DuPont de Nemours Inc trades at $144.39 (market cap $19.51B). The key difference: Amgen, Inc. is far larger — about 11.5× DuPont de Nemours Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | DD | |
|---|---|---|
Market Cap | $224.14B | $19.51B |
Sector | Health | Basic Materials |
52-Week High | $417.20 | $154.59 |
52-Week Low | $271.18 | $90.24 |
Enterprise Value | $267.45B | $20.90B |
Dividend Yield | 2.43% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
DuPont (DD) trades at $141.56, down 0.65% over the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and aerospace demand, leading to a raised full-year 2026 outlook. The stock exhibits a high P/E ratio of 62.01, reflecting growth expectations, while net income margin remains thin at 0.79%.
Outlook is positive due to earnings momentum and strategic initiatives in water treatment and lithium extraction, but risks include legal settlements over PFAS chemicals and volatile cash flows. With a consensus price target of $232.80 implying significant upside, the stock offers growth potential tempered by execution and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
